Maytansinol is primarily used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Its potent cytotoxic properties make it an effective payload in these conjugates, where it is attached to monoclonal antibodies that specifically recognize and bind to cancer cells. This targeted approach allows for the delivery of the cytotoxic agent directly to tumor cells, minimizing damage to healthy tissues and reducing systemic side effects. Maytansinol-based ADCs have shown promise in treating various cancers, including breast cancer and lymphoma, by inhibiting cell division and inducing apoptosis in malignant cells. Its application in precision medicine continues to be a significant area of research in oncology.